TD Cowen on Acadia Pharmaceuticals (ACAD): 'Expanded DAYBUE Salesforce to Drive LT Growth'
Tweet Send to a Friend
TD Cowen analyst Ritu Baral reiterated a Buy rating and $35.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
